SCHEMBL2124451

SCHEMBL2124451

Cc1ccc(Nc2c(-c3ccco3)nc3c(C#N)c[nH]n23)c(C)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 9/20 0.54
▸ GAA P10253 5/20 0.47
▸ TP53 P04637 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MAPT P10636 4/20 0.41
▸ POLB P06746 1/20 0.38
▸ HPGD P15428 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KDM6B O15054 1/20 0.37
▸ KDM5C P41229 1/20 0.37
▸ KDM5D Q9BY66 1/20 0.37
▸ KDM4C Q9H3R0 1/20 0.37
▸ KDM5B Q9UGL1 1/20 0.37
▸ PHF8 Q9UPP1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124746 0.84 KDM5A (0.52) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2876505 0.83 MAPT (0.43) KDM5ATP53MAPTKDM4EALDH1A1
SCHEMBL2125420 0.83 KDM5A (0.54) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2123274 0.83 KDM5A (0.57) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2125673 0.81 KDM5A (0.51) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2124502 0.81 KDM5A (0.53) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2125909 0.80 GAA (0.49) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2124113 0.80 KDM5A (0.46) KDM5ATP53MAPTKDM6BKDM5C
SCHEMBL2123747 0.80 GAA (0.45) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2122447 0.80 KDM5A (0.53) KDM5AGAATP53MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885GAA 502/4885TP53 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback